AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03111459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Valiant Thoracoabdominal Stent Graft System
Description: The Medtronic Valiant Thoracoabdominal Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components The system is comprised of two investigational devices that include the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
Study NCT02925598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel LMA insertion
Description: 'I-gel LMA insertion' was done following anesthesia induction.
Study NCT02925598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuraGain LMA insertion
Description: 'AuraGain LMA insertion' was done following anesthesia induction.
Study NCT02925598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETT insertion
Description: 'ETT insertion' was done following anesthesia induction.
Study NCT00548262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
Study NCT00548262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if \<40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if \<40 kg body weight).
Study NCT03904225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-Gimeracil-Oteracil
Description: oral administration for 12 months
Study NCT02266823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Theory
Description: The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
Study NCT02266823 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social Cognitive Theory
Description: The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
Study NCT01255215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
Study NCT01255215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Nitric Oxide
Description: Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
Study NCT03212495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamedetomidine
Description: intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
Study NCT03261076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategies Enhancing Reading in Older Underperf. Students
Description: Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
Study NCT04388410 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: convalescent plasma
Description: Plasma obtained from volunteers who have recovered from SARS-Cov-2 infection. Two 200 ml infusions will be administered with 24-72 hours in between.
Study NCT04388410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: convalescent plasma
Description: Plasma obtained from volunteers who have recovered from SARS-Cov-2 infection. Two 200 ml infusions will be administered with 24-72 hours in between.
Study NCT01088555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium thiosulfate
Description: Oral administration of sodium thiosulfate pentahydrate 5% solution (American Regent) 10ml BID x 7 days
Study NCT03848559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway management with a submerged model
Description: Airway management with a submerged manikin using different airway devices in randomized order
Study NCT02356120 — intervention group
Intervention type: OTHER
Intervention: Echocardiogram
Description: Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
Study NCT01819675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS
Study NCT01819675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency rTMS
Study NCT01819675 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Study NCT03212495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
Study NCT01472549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine-alcohol
Description: Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.
Study NCT01472549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Description: Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation
Study NCT03055052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula for preterm infants
Description: Reconstituted in water and given to infants at more than 50% of feedings.
Study NCT03055052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formula with higher protein and new fat blend for preterm infants
Description: Reconstituted in water and given to infants at more than 50% of feedings.
Study NCT01048801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid diagnostic test
Description: Use of rapid daignostic tests for diagnosis of malaria
Study NCT01048801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: presumptive malaria treatment
Description: Treatment of malariabased on clinical diagnosis without use of diagnostic test
Study NCT01769326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hand exercise
Description: Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
Study NCT01769326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MusicGlove
Description: The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
Study NCT01769326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Arm Exercise
Description: Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
Study NCT01769326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resonating Arm Exerciser
Description: The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
Study NCT04698759 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: no Intervention
Study NCT01056718 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nebivolol
Description: Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
Study NCT02080559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB
Description: 0.5ml IM
Study NCT02080559 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4CMenB
Description: 0.5ml IM
Study NCT01477307 — intervention group
Intervention type: OTHER
Intervention: Hypocaloric diet
Description: Eurodiet,standardized hypo-caloric diet, during 3 weeks
Study NCT03190824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: A novel, replication-competent Ad5 based adenoviral construct that incorporates a human telomerase reverse transcriptase gene (hTERT) promoter.
Study NCT03266900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: re-TURBT
Description: 2nd bladder biopsy within 4-6 weeks of initial biopsy
Study NCT03266900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 weeks BCG instillation
Description: standard 6 weeks of BCG induction
Study NCT03540693 — intervention group
Intervention type: PROCEDURE
Intervention: RYGB
Description: RYGB-weight loss surgery
Study NCT03540693 — intervention group
Intervention type: PROCEDURE
Intervention: SG
Description: SG- weight loss surgery
Study NCT03540693 — intervention group
Intervention type: PROCEDURE
Intervention: LAGB
Description: LAGB- weight loss surgery
Study NCT03286101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Ivermectin lotion
Description: The intervention is composed of a single application of the 0.5% ivermectin lotion.
Study NCT03286101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: The intervention is composed of a single application of the vehicle control.
Study NCT01995669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01995669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01995669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT00926250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral PS-IPC supplement
Description: Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
Study NCT00926250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
Study NCT00421278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0633
Description: Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
Study NCT05105074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
Study NCT05105074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
Study NCT01367639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR) program
Description: The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life
Study NCT00864253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
Study NCT00864253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
Study NCT03309813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExAblate
Description: ExAblate Thalamotomy for Chronic Trigeminal Neuropathic Pain
Study NCT03309813 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial ExAblate
Description: Sham ExAblate Thalamotomy procedure
Study NCT03309813 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Crossover Transcranial Exablate
Description: Subjects randomized to the Sham Exablate could opt for the Crossovover Transcranial Exablate Arm (Exablate Thalamotomy) after completing the Month 3 visit in the Sham Arm.
Study NCT05249491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological evaluation of dental plaques with children with or without black tooth stain
Description: Evaluation of the etiological factors of black tooth stain according to the questionnaire
Study NCT03896620 — intervention group
Intervention type: DEVICE
Intervention: Preoperative RT
Description: Radiation delivered before surgery.
Study NCT03896620 — intervention group
Intervention type: DEVICE
Intervention: Postoperative RT
Description: Radiation delivered after surgery.
Study NCT03896620 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Physician's choice of chemotherapy.
Study NCT03896620 — intervention group
Intervention type: OTHER
Intervention: Surgery
Description: Surgical excision of tumor.
Study NCT02831023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
Study NCT02831023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine
Description: Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
Study NCT02831023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg primaquine
Description: Primaquine will be administered in an aqueous solution according to weight-based dosing.
Study NCT02831023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
Study NCT02831023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene blue
Description: Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
Study NCT02831023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine
Description: Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
Study NCT02831023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
Study NCT02989818 — intervention group
Intervention type: OTHER
Intervention: Endoscopic Submucosal Dissection
Description: This intervention is part of the subjects standard of care and is a method to remove the Gastrointestinal lesion.
Study NCT00700778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin
Study NCT00700778 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Study NCT00700778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00700778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00700778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Study NCT03538301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 (Low Dose)
Description: Intravenous administration every 2 weeks
Study NCT03538301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201 (High Dose)
Description: Intravenous administration every 2 weeks
Study NCT03538301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Saline
Study NCT00763776 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: clamp crushing technique
Description: Liver transection during hepatectomy by clamp crushing technique
Study NCT00763776 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasonic dissector
Description: Liver transection during hepatectomy by the ultrasonic dissector
Study NCT02571595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy for insomnia (dCBT-I)
Description: dCBT-I is a computer-based treatment intervention that provides strategies to improve sleep and daytime function (concentration, productivity) in individuals with insomnia
Study NCT03000205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypertonic dextrose water
Description: 20% hypertonic dextrose water injection for chronic shoulder pain at Week0
Study NCT03000205 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline and Lidocaine.
Description: Normal Saline injection for chronic shoulder pain at Week0 (Arms:Placebo Comparator: Placebo)
Study NCT02654353 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablation
Description: In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
Study NCT02654353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
Study NCT02005042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on smartphone
Description: Receive personalized feedback (EMI) on smartphone regarding physical activity
Study NCT01422642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: legacy posterior stabilized high-flexion (NexGen LPS-Flex)
Description: NexGen legacy posterior stabilized high-flexion (NexGen LPS-Flex) total knee system
Study NCT01422642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: legacy posterior stabilized standard (NexGen LPS)
Description: NexGen legacy posterior stabilized standard (NexGen LPS) total knee system
Study NCT02842151 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manifest refraction
Description: Manifest refraction performed by autorefraction (automated) and manual procedures (standard)
Study NCT02842151 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ACRYSOF® IQ Monofocal IOL Model SN60WF
Description: Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
Study NCT02842151 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Topcon® KR-1W Wave-Front Analyzer
Description: Wavefront and topography system used to obtain autorefraction data
Study NCT00591851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
Description: AC \[Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)\] Followed By Paclitaxel (P)
Study NCT02758067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brexpiprazole
Description: 2- 4 mg/day, tablets, oral, 28-weeks
Study NCT02758067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: 4-6 mg/day, tablets, oral, 28-weeks